Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Trial records in obesity and overweight in adults — page 8

208 records bearing on obesity and overweight in adults.

Showing 0 records on this page

Records

208 documents · page 8 of 9

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
REDEFINE-4CagriSema (cagrilintide with semaglutide)Phase 3OngoingRandomised, double-blind, active-controlledNot rated
AMY-PH1-ORALprogramme recordCagrilintidePhase 1ReportedPhase 1 ascending doseVery low
AMY-PH1B-SCprogramme recordCagrilintidePhase 1ReportedPhase 1 ascending doseVery low
SYNCHRONIZE-1SurvodutidePhase 3OngoingRandomised, double-blind, placebo-controlledNot rated
SYNCHRONIZE-2SurvodutidePhase 3OngoingRandomised, double-blind, placebo-controlledNot rated
SYNCHRONIZE-CVOTSurvodutidePhase 3OngoingEvent-driven cardiovascular outcome trialNot rated
PETRE-PH2-OBESITYPetrelintidePhase 2OngoingRandomised, double-blind, placebo-controlledNot rated
DREAMS-3MazdutidePhase 3OngoingRandomised, double-blind, active-controlledNot rated
MARITIDE-PH3Maridebart cafraglutidePhase 3OngoingRandomised, double-blind, placebo-controlledNot rated
TRIUMPH-1-RENAL-IMPprogramme recordRetatrutidePhase 1OngoingPhase 1 ascending doseVery low
TRIUMPH-2-REGIONAL-CNprogramme recordRetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low
TRIUMPH-3-OLEprogramme recordRetatrutidePhase 3OngoingSingle-arm open-labelVery low
TRIUMPH-4-BODY-COMPprogramme recordRetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low
REDEFINE-4-RENAL-IMPprogramme recordCagriSema (cagrilintide with semaglutide)Phase 1OngoingPhase 1 ascending doseVery low
SYNCHRONIZE-1-ELDERLYprogramme recordSurvodutidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low
SYNCHRONIZE-2-REGIONAL-JPprogramme recordSurvodutidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low
SYNCHRONIZE-CVOT-RENAL-IMPprogramme recordSurvodutidePhase 1OngoingPhase 1 ascending doseVery low
MARITIDE-PH3-RENAL-IMPprogramme recordMaridebart cafraglutidePhase 1OngoingPhase 1 ascending doseVery low
DREAMS-3-BODY-COMPprogramme recordMazdutidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low
PETRE-PH2-OBESITY-REGIONAL-JPprogramme recordPetrelintidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low
TRIUMPH-1-PKprogramme recordRetatrutidePhase 1OngoingPhase 1 ascending doseVery low
TRIUMPH-2-QOLprogramme recordRetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low
TRIUMPH-4-REGIONAL-JPprogramme recordRetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low
REDEFINE-4-PKprogramme recordCagriSema (cagrilintide with semaglutide)Phase 1OngoingPhase 1 ascending doseVery low

page 8 of 9

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.